CD133 Expression in Pancreatic Cancer
Author Information
Author(s): Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S
Primary Institution: Kagoshima University Graduate School of Medical and Dental Science
Hypothesis
This study investigates the relationship between CD133 expression and clinicopathological factors in pancreatic cancer.
Conclusion
CD133 expression in pancreatic cancer is significantly associated with lymphatic metastasis, VEGF-C expression, and prognosis.
Supporting Evidence
- 60% of pancreatic cancer specimens were found to be CD133-positive.
- CD133 expression correlated significantly with lymph node metastasis (P=0.0024).
- Patients with CD133-positive tumors had a significantly lower 5-year survival rate (P=0.0002).
- CD133 expression was an independent prognostic factor (P=0.0103).
- VEGF-C expression was significantly correlated with CD133 expression (P=0.0002).
Takeaway
The study found that a marker called CD133 is linked to how aggressive pancreatic cancer is and how well patients might do.
Methodology
Immunohistochemical assessment of CD133 and other markers in pancreatic head carcinoma specimens from 80 patients.
Participant Demographics
52 male and 28 female patients, aged 42–80 years (mean 66.0 years).
Statistical Information
P-Value
P=0.0002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website